Side Effects of doravirine: A Synthesis of Findings from 6 Studies

  1. Home
  2. Side Effects of doravirine
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of doravirine: A Synthesis of Findings from 6 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of doravirine: A Synthesis of Findings from 6 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Doravirine is a promising new HIV medication that has been shown to be effective in treating HIV-infected individuals. 4 study found that doravirine was non-inferior to ritonavir-boosted darunavir in a group of adults with previously untreated HIV-1 infection. Another study, 3 , also demonstrated the effectiveness of doravirine in treating HIV-infected individuals.

Reasons for Side Effects

Doravirine is a medication that inhibits the growth of HIV. It works by inhibiting the reverse transcriptase of HIV, which is an enzyme that HIV uses to convert its genetic information into the genetic information of the host cell after it enters the host cell. Doravirine binds to reverse transcriptase and inhibits its function, thereby inhibiting the growth of HIV. However, it's possible that doravirine may also affect other cells in the body, leading to side effects.

Common Side Effects

Gastrointestinal

Doravirine can cause gastrointestinal side effects. 4 study reported diarrhea, nausea, and vomiting as side effects of doravirine.

Psychoneurological

Doravirine can cause psychoneurological side effects. 1 study reported depression, anxiety, and insomnia as side effects of doravirine.

Skin

Doravirine can cause skin side effects. 4 study reported rash and itching as side effects of doravirine.

Side Effect Management

Gastrointestinal Side Effects

Dietary and drug therapies can be used to reduce gastrointestinal side effects from doravirine. Dietary therapy involves eating easily digestible foods and avoiding stimulants. Drug therapy includes prescribing antiemetics and antidiarrheals.

Psychoneurological Side Effects

Psychotherapy and drug therapy can be used to reduce psychoneurological side effects from doravirine. Psychotherapy includes counseling and cognitive behavioral therapy, which are effective. Drug therapy includes prescribing antidepressants and anxiolytics.

Skin Side Effects

Moisturizers and steroid creams are prescribed to reduce skin side effects from doravirine.

Comparison Between Studies

Similarities in Studies

Multiple studies have shown that doravirine is an effective drug for treating HIV-infected individuals. In addition, doravirine is expected to be a drug with fewer side effects compared to conventional HIV medications.

Differences in Studies

Research results on doravirine side effects may vary depending on the study. 4 study reported diarrhea, nausea, and vomiting as side effects of doravirine, but these side effects were not reported in 3 study. This difference may be explained by differences in the characteristics of the patients participating in the study and the methods of the study.

Precautions for Applying to Real Life

Doravirine is an effective drug for treating HIV-infected individuals, but side effects vary from person to person. Therefore, it is important to carefully follow your doctor's instructions when taking doravirine and consult your doctor immediately if you experience any side effects.

Limitations of Current Research

Research on doravirine side effects is still insufficient. In particular, there are still many unknowns about long-term side effects. Therefore, it is important to see your doctor regularly if you are taking doravirine long-term.

Future Research Directions

Further research is needed on doravirine side effects. In particular, research is needed on long-term side effects, interactions between doravirine and other drugs, and the safety of doravirine.

Conclusion

Doravirine is an effective drug for treating HIV-infected individuals, but there is a risk of side effects. When taking doravirine, carefully follow your doctor's instructions and consult your doctor immediately if you experience any side effects. Further research on doravirine side effects is needed, and research on long-term side effects, interactions between doravirine and other drugs, and the safety of doravirine is expected.

Literature analysis of 6 papers
Positive Content
5
Neutral Content
1
Negative Content
0
Article Type
2
0
0
2
6
1.

An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors.

Author: SennekerTessa, TsengAlice

NPAE management
Neuropsychiatric adverse effects

Neuropsychiatric adverse effects (NPAE) are a growing concern with integrase strand transfer inhibitors (INSTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs). This paper reviews the incidence, risk factors, and management of NPAE with these drugs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

2.

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.

Author: DevredInès, KayembeKick, ValinNadia, RougierHayette, ShingaBruce Wuembulua, Lambert-NiclotSidonie, ChiarabiniThibault, MeyohasMarie-Caroline, LacombeKarine

HIV PEP

This study compares the completion rates of doravirine/tenofovir disoproxil fumarate/lamivudine (DOR/3TC/TDF) and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/c/FTC/TAF) for HIV post-exposure prophylaxis (PEP). The study found that DOR/3TC/TDF had a similar safety profile to EVG/c/FTC/TAF, with a comparable completion rate and no cases of seroconversion. DOR/3TC/TDF may be a cost-effective treatment option for PEP in the context of HIV-exposure accidents.

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

3.

A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals.

Author: SchürmannDirk, SobothaChristian, GilmartinJocelyn, RobberechtsMartine, De LepeleireInge, YeeKa Lai, GuoYing, LiuRachael, WagnerFrank, WagnerJohn A, ButtertonJoan R, AndersonMatt S

Antiviral activity
Doravirine monotherapy
Well tolerated
Elevated liver enzymes

Doravirine monotherapy demonstrated robust antiviral activity without evidence of viral resistance and was generally well tolerated in HIV-infected men.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

Author: MolinaJean-Michel, SquiresKathleen, SaxPaul E, CahnPedro, LombaardJohan, DeJesusEdwin, LaiMing-Tain, XuXia, RodgersAnthony, LupinacciLisa, KumarSushma, SklarPeter, NguyenBach-Yen, HannaGeorge J, HwangCarey,

HIV treatment

Doravirine, a novel NNRTI, showed comparable efficacy to ritonavir-boosted darunavir in adults with previously untreated HIV-1 infection, demonstrating its potential as an alternative treatment option.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Emerging reverse transcriptase inhibitors for HIV-1 infection.

Author: RaiMohammad A, PannekSam, FichtenbaumCarl J

Fewer side effects
Improved ART
Longer-acting agents
Reduced drug interactions
Drug resistance

Four new agents, GS-9131, MK-8591, Elsulfavirine and Doravirine, are showing promise as potential improvements to antiretroviral therapy (ART) for HIV. These newer agents have longer half-lives, more favorable adverse effect profiles, and fewer drug interactions.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa.

Author: SteegenKim, MoorhouseMichelle, WensingAnnemarie Mj, VenterWillem Df, HansLucia

Better tolerability
Formidable resistance profile
Side effects

This study investigated the resistance profile of doravirine, an HIV drug, in South Africa. The findings suggest that doravirine may be a suitable alternative to dolutegravir for HIV treatment in this region.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.